Qualigen Therapeutics (FRA:7R90) Change In Receivables : €0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Qualigen Therapeutics Change In Receivables?

Qualigen Therapeutics's change in receivables for the quarter that ended in Sep. 2024 was €0.00 Mil. It means Qualigen Therapeutics's Accounts Receivable stayed the same from Jun. 2024 to Sep. 2024 .

Qualigen Therapeutics's change in receivables for the fiscal year that ended in Dec. 2023 was €0.00 Mil. It means Qualigen Therapeutics's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .

Qualigen Therapeutics's Accounts Receivable for the quarter that ended in Sep. 2024 was €0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Qualigen Therapeutics's liquidation value for the three months ended in Sep. 2024 was €-3.66 Mil.

Qualigen Therapeutics Change In Receivables Historical Data

The historical data trend for Qualigen Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qualigen Therapeutics Change In Receivables Chart

Qualigen Therapeutics Annual Data

Trend

Mar20

Dec21

Dec22

Dec23

Change In Receivables

0.12

0.04

0.40

Qualigen Therapeutics Quarterly Data
	Sep19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Qualigen Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Qualigen Therapeutics (FRA:7R90) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Qualigen Therapeutics's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Qualigen Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Qualigen Therapeutics's liquidation value for the quarter that ended in Sep. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.35	-	4.013	+	0.75 * 0	+	0.5 * 0
=	-3.66

Qualigen Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Qualigen Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Qualigen Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Qualigen Therapeutics Inc (FRA:7R90) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

QLGN:USA 7R90:Germany

Address

5857 Owens Avenue, Suite 300, Carlsbad, CA, USA, 92008

Website

https://www.qlgntx.com

Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.

Qualigen Therapeutics Headlines

No Headlines